If you have been reading about alpha-MSH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
With 5.8 percent annual growth rate during the period 2001–2016, aquaculture continues to grow faster than other major food production sectors, but it no longer has the high annual growth rates experienced in the 1980s and 1990s. In 2012, the total world production of fisheries was 158 million tonnes, of which aquaculture contributed 66.6 million tonnes, about 42%. The growth rate of worldwide aquaculture has been sustained and rapid, averaging about 8% per year for over 30 years, while the take from wild fisheries has been essentially flat for the last decade. The aquaculture market reached $86 billion in 2009. Aquaculture is an especially important economic activity in China. Between 1980 and 1997, the Chinese Bureau of Fisheries reports, aquaculture harvests grew at an annual rate of 16.7%, jumping from 1.9 million tonnes to nearly 23 million tonnes. In 2005, China accounted for 70% of world production. Aquaculture is also currently one of the fastest-growing areas of food production in the U.S. About 90% of all U.S. shrimp consumption is farmed and imported. In recent years, salmon aquaculture has become a major export in southern Chile, especially in Puerto Montt, Chile's fastest-growing city. A United Nations report titled The State of the World Fisheries and Aquaculture released in May 2014 maintained fisheries and aquaculture support the livelihoods of some 60 million people in Asia and Africa. FAO estimates that in 2016, overall, women accounted for nearly 14 percent of all people directly engaged in the fisheries and aquaculture primary sector.
Britain gathered allies to form the Third Coalition against The French Empire after Napoleon was self-proclaimed as emperor. In response, Napoleon seriously considered an invasion of Great Britain, massing 180,000 troops at Boulogne. Before he could invade, he needed to achieve naval superiority—or at least to pull the British fleet away from the English Channel. A complex plan to distract the British by threatening their possessions in the West Indies failed when a Franco-Spanish fleet under Admiral Villeneuve turned back after an indecisive action off Cape Finisterre on 22 July 1805. The Royal Navy blockaded Villeneuve in Cádiz until he left for Naples on 19 October; the British squadron caught and overwhelmingly defeated a Franco-Spanish fleet in the Battle of Trafalgar on 21 October (the British commander, Lord Nelson, died in the battle). Napoleon never again had the opportunity to challenge the British at sea, nor to threaten an invasion. He again turned his attention to the enemies on the Continent.
Signaling peptide receptor is a type of receptor which binds one or more signaling peptides or signaling proteins. An example is the tropomyosin receptor kinase B (TrkB), which is bound and activated by the neurotrophic protein brain-derived neurotrophic factor (BDNF). Another example is the μ-opioid receptor (MOR), which is bound and activated by the opioid peptide hormone β-endorphin.
An orphan drug is a pharmaceutical agent that is developed to treat certain rare medical conditions. An orphan drug would not be profitable to produce without government assistance, due to the small population of patients affected by the conditions. The conditions that orphan drugs are used to treat are referred to as orphan diseases. The assignment of orphan status to a disease and to drugs developed to treat it is a matter of public policy that depends on the legislation (if there is any) of the country. Designation of a drug as an orphan drug has yielded medical breakthroughs that might not otherwise have been achieved, due to the economics of drug research and development. For example, in the U.S. and the EU, it is easier to gain marketing approval for an orphan drug. There may be other financial incentives, such as an extended period of exclusivity, during which the producer has sole rights to market the drug. All are intended to encourage development of drugs which would otherwise lack sufficient profit motive to attract corporate research budgets and personnel.
Sources: en.wikipedia.org
=== Pharmacology applications === The development of NanoSIMS for organo-metallic drugs paved the way for exploring the distribution of biologically active molecules at the subcellular level. Legin et al. combined NanoSIMS with fluorescence confocal laser scanning microscopy to characterize the subcellular distribution of 15N isotopically labeled Pt-bearing cisplatin in human colon cancer cells. Cisplatin appears in the targeted nucleus of the colon cancer cells. 15N and Pt are separated showing subcellular metabolism is in the path of action. The internalization of amiodarone into the lysosomes of macrophages is illustrated in Jiang et al. Thanks to low detection limit, two iodine atoms of 127I in amiodarone molecule enables a label-free imaging by NanoSIMS. Iodine and phosphorus imaging along with plotting the intensity of 127I− vs 31P− indicated a linear relationship between the amount of iodine and phospholipids. These results disclose evidence of amiodarone-induced phospholipidosis. He et al. visualized the distribution of therapeutic antisense oligonucleotides labelled with bromine (Br-ASO) in some varieties of cultured cells and importantly mouse tissues (heart, kidney, and Liver) using NanoSIMS data combined with back scattered electron microscopy. They demonstrated that phosphorothioate ASOs associate with filopodia and the inner nuclear membrane of cells. They also documented essential cellular and subcellular heterogeneity in ASO distribution in the mouse tissues. Becquart et al.
By the early 1940s, Rausing (now the sole owner of the company) began developing dairy packaging that could compete with loose milk. Erik Wallenberg, an assistant in the Åkerlund & Rausing lab, came up with the idea to construct a tetrahedron-shaped package out of a tube of paper in 1944. On 27 March 1944, Rausing filed a patent for the idea. Rausing's wife Elisabeth reportedly came up with the idea of continuously sealing the packages through the milk while filling the tube in the manner of stuffing sausages. In 1946, the company introduced the first prototype tetrahedron-package filling machine.
=== Season 1 === At the Great Council of 101 AC, King Jaehaerys I Targaryen's eldest male descendant Prince Viserys Targaryen is chosen to be the heir to the Iron Throne over his eldest descendant Princess Rhaenys Targaryen. In a time skip to the ninth year of Viserys' reign, his wife Queen Aemma Arryn is pregnant with a son, having experienced several previous miscarriages. At a great tournament celebrating the impending birth of Viserys' son, the Hand of the King Ser Otto Hightower warns Viserys against making his brutish younger brother Prince Daemon Targaryen his heir over his daughter Princess Rhaenyra Targaryen, but Viserys ignores Otto's advice. Viserys departs the tourney to be present as Aemma gives birth, but finds Aemma and the baby's lives to be at risk. He authorizes Grand Maester Mellos to perform a caesarian section in order to save the baby, completely aware that the procedure will kill Aemma. Aemma dies in agony giving birth to their son Baelon, who passes away a day later in infancy. Otto has his daughter Lady Alicent Hightower console Viserys, and informs the small council that Daemon drunkingly referred to the deceased Baelon as "the heir for a day". An enraged Viserys confronts Daemon, who complains that he never had any support for him and insults Viserys as a weak king who is easily manipulated by Otto and his circle. He exiles Daemon to the Vale to consummate his marriage to Lady Rhea Royce, and removes Daemon's status as Viserys' heir with Rhaenyra.
When injected into the base of the penis, alprostadil may cause penile pain, dizziness, headache, high blood pressure, Peyronie disease, and burning at the injection site. When inserted into the urethra, alprostadil may cause urethral burning, penile pain, dizziness, headache, and urethral bleeding. When someone engages in vaginal sex after using an alprostadil urethral suppository, their partner may experience vaginal itching. Clinical trials for the treatment showed positive results in around 3,000 men that it was tested on; it is said to be usable by men with diabetes or heart problems and those who have undergone a prostatectomy.
November 22: DN Aidit, Chairman of Communist Party of Indonesia, is executed by the Indonesian Army in Boyolali after becoming a fugitive as a consequence of the 30 September Movement which are blamed on the Communist Party of Indonesia. December 4: The Gemini 7 completes 206 orbits around the Earth, equating to roughly one trip to the Moon.
Sources: en.wikipedia.org
=== Urban decay === Detroit has experienced significant urban decay—the process in which a previously flourishing city falls into disuse and disrepair, characterized commonly by empty plots of land, abandoned, decrepit, and often vandalized buildings, high unemployment rates, and high crime rates. Detroit has become one of the most infamous examples of such cities in the United States. Abandoned residential and commercial buildings are widespread; in 2014, 30% of residential buildings in the city were partially or fully vacant. The problem is so severe that the city has been likened to a ghost town. In the 1940s, Detroit was the fourth-largest city in the U.S. thanks in large part to the automobile industry. Vehicle manufacturers Ford, General Motors, and Chrysler had their factories there, which made the city a source of employment for many people. In the 1950s, the industry was no longer confined to Detroit; it began to spread out when vehicle manufacturers began to move their factories elsewhere, which led to the old factories being closed and abandoned, and eventually, many of them were vandalized. This was a side effect of automation and globalization. While improvements have been made, blight remains specifically in predominantly African American neighborhoods. A significant percentage of housing parcels in the city are vacant, with abandoned lots making up more than half of total residential lots in large portions of the city. With at least 70,000 abandoned buildings, 31,000 empty houses, and 90,000 vacant lots, Detroit has become notorious for its urban blight.
=== Blood tests === In someone suspected of having cholecystitis, blood tests are performed for markers of inflammation (e.g. complete blood count, C-reactive protein), as well as bilirubin levels in order to assess for bile duct blockage. Complete blood count typically shows an increased white blood count (12,000–15,000/mcL). C-reactive protein is usually elevated although not commonly measured in the United States. Bilirubin levels are often mildly elevated (1–4 mg/dL). If bilirubin levels are more significantly elevated, alternate or additional diagnoses should be considered such as gallstone blocking the common bile duct (common bile duct stone). Less commonly, blood aminotransferases are elevated. The degree of elevation of these laboratory values may depend on the degree of inflammation of the gallbladder.
Genomic Technologies, Inc. was one of the few companies to develop a large scale oligonucleotide synthesizer that was, from the ground up, an oligonucleotide synthesizer. The initial platform called the VLSS for very large scale synthesizer utilized large Pharmacia liquid chromatograph columns as reactors and could synthesize up to 75 mmol of material. Many oligonucleotide synthesis factories designed and manufactured their own custom platforms and little is known due to the designs being proprietary. The VLSS design continued to be refined and is continued in the QMaster synthesizer which is a scaled down platform providing milligram to gram amounts of synthetic oligonucleotide. The current practices of synthesis of chemically modified oligonucleotides on large scale have been recently reviewed.
Bats are the only mammals capable of sustained flight, as opposed to the gliding of flying squirrels, colugos and sugar gliders. The fastest bat, the Mexican free-tailed bat (Tadarida brasiliensis), can achieve a ground speed of 160 km/h (100 mph).
== Interaction with integrin α2β1 == Cellular receptors for collagens belong to the family of β1 integrins. Collagen XXIII interacts in an ion-and conformation-dependent manner with integrin α2β1. Integrin α2β1 is a collagen-binding integrin present at the epidermis, therefore this is the location where the interaction takes place. Both proteins co-localize on basal keratinocytes surface.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.